Bank of America Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by equities research analysts at Bank of America from $101.00 to $104.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s target price suggests a potential upside of 22.80% from the company’s current price.

BBIO has been the subject of several other research reports. Wells Fargo & Company boosted their price objective on BridgeBio Pharma from $98.00 to $102.00 and gave the company an “overweight” rating in a report on Tuesday. Truist Financial lifted their price target on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings restated a “sell (d)” rating on shares of BridgeBio Pharma in a report on Friday, May 15th. Piper Sandler upped their price objective on shares of BridgeBio Pharma from $111.00 to $115.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, HC Wainwright raised their price objective on shares of BridgeBio Pharma from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $99.53.

BridgeBio Pharma Price Performance

Shares of BridgeBio Pharma stock traded up $0.02 during trading on Tuesday, reaching $84.69. 1,245,358 shares of the company traded hands, compared to its average volume of 2,992,219. The firm has a market capitalization of $16.56 billion, a PE ratio of -22.66 and a beta of 0.96. BridgeBio Pharma has a 1-year low of $46.81 and a 1-year high of $93.42. The company has a 50 day moving average price of $76.07 and a 200-day moving average price of $73.03.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The business had revenue of $243.68 million for the quarter, compared to analysts’ expectations of $220.91 million. The company’s quarterly revenue was up 120.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.95) earnings per share. Equities research analysts expect that BridgeBio Pharma will post -2.31 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Hannah Valantine sold 2,196 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $68.57, for a total transaction of $150,579.72. Following the completion of the sale, the director owned 9,259 shares in the company, valued at $634,889.63. This trade represents a 19.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer E. Cook sold 148,589 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the sale, the director owned 8,383 shares of the company’s stock, valued at approximately $742,230.82. The trade was a 94.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 392,117 shares of company stock valued at $29,934,700. Company insiders own 14.23% of the company’s stock.

Institutional Trading of BridgeBio Pharma

Large investors have recently bought and sold shares of the company. First Bank & Trust increased its holdings in BridgeBio Pharma by 1.6% in the 2nd quarter. First Bank & Trust now owns 8,797 shares of the company’s stock worth $655,000 after acquiring an additional 142 shares during the last quarter. GAMMA Investing LLC raised its position in shares of BridgeBio Pharma by 13.8% in the second quarter. GAMMA Investing LLC now owns 1,646 shares of the company’s stock valued at $123,000 after purchasing an additional 199 shares during the period. Commonwealth Equity Services LLC lifted its stake in shares of BridgeBio Pharma by 4.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock valued at $396,000 after buying an additional 244 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after buying an additional 245 shares during the period. Finally, State of New Jersey Common Pension Fund D boosted its holdings in BridgeBio Pharma by 0.5% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company’s stock worth $3,970,000 after buying an additional 246 shares during the period. 99.85% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Analysts raise targets: Piper Sandler increased its price target from $111 to $115 and maintained an “overweight” rating. Wells Fargo also raised its target, from $98 to $102, while keeping an “overweight” rating. The revisions imply substantial potential upside and reflect continued confidence in BridgeBio’s development pipeline. Benzinga analyst price-target updates
• Positive Sentiment: Pipeline catalysts could drive sentiment: BridgeBio is listed among biotech companies with major second-half 2026 catalysts, including potential regulatory decisions and late-stage clinical-trial readouts. Positive data or approvals could provide important valuation catalysts for BBIO. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Neutral Sentiment: Revenue growth was strong: Second-quarter revenue reached $243.7 million, beating the $220.9 million consensus estimate and increasing 120.4% from the prior year. The improvement suggests commercial and partnered-product activity is expanding, although investors remain focused on the company’s path toward profitability. BridgeBio Pharma Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Quarterly loss exceeded expectations: BridgeBio reported a second-quarter loss of $0.78 per share, wider than the $0.58 analyst consensus, despite improving from a $0.95 loss per share a year earlier. The earnings miss may limit the stock’s near-term upside and reinforce concerns about ongoing cash needs and operating costs. BridgeBio Pharma Q2 Earnings Results and Conference Call

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.